Ifabotuzumab

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameIfabotuzumab
Drug Alias NameHumaneered antibodyAnti-EphA3 monoclonal antibodyIgG1-kappa antibodyAnti-EphA3 MAbIgG1K antibody +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEphrin type-A receptor 3 inhibitors
TargetsEphrin type-A receptor 3
Therapy Area/IndicationsPrimary MyelofibrosisMyelodysplastic SyndromesGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesTaran Therapeutics IncHumanigen IncOlivia Newton-John Cancer Research Institute
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsPrimary MyelofibrosisMyelodysplastic Syndromes

Other Information

ATC CodeN/A
Related LinksN/A